Inhibrx Reports Positive Phase 1/2 Data for Ozekibart in Colorectal Cancer, Plans FDA Filing for Chondrosarcoma
核心洞察
Inhibrx Biosciences reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) combined with FOLFIRI (搜索) in patients with locally advanced or metastatic colorectal cancer (搜索).
The company announced plans to submit a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma (搜索) by April 2026.
Transcenta (搜索) holds exclusive rights to develop and commercialize ozekibart in Greater China through its subsidiary HJB (搜索) and is actively evaluating regional development plans.
Inhibrx Biosciences has reported encouraging interim results from its Phase 1/2 clinical trial evaluating ozekibart (INBRX-109) in combination with FOLFIRI (搜索) chemotherapy for patients with locally advanced or metastatic, unresectable colorectal cancer (搜索) (CRC). The company also announced its intention to submit a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma (搜索) by April 2026.
Clinical Trial Progress in Colorectal Cancer
The Phase 1/2 study represents a significant milestone for ozekibart, demonstrating positive updated interim data in the challenging indication of advanced colorectal cancer (搜索). The trial evaluated the drug in combination with FOLFIRI (搜索), a standard chemotherapy regimen consisting of folinic acid, fluorouracil, and irinotecan, in patients with locally advanced or metastatic, unresectable disease.
Regulatory Pathway for Chondrosarcoma
Beyond colorectal cancer (搜索), Inhibrx has outlined a clear regulatory strategy for ozekibart in conventional chondrosarcoma (搜索), a rare bone and soft tissue cancer. The planned BLA submission to the FDA by April 2026 indicates the company's confidence in the drug's potential across multiple oncology indications.
Greater China Development Rights
Transcenta (搜索) holds exclusive rights to develop and commercialize ozekibart in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB (搜索), a wholly owned subsidiary of the company. Following the positive developments reported by Inhibrx, Transcenta is actively evaluating its development plans for the Greater China region.
The partnership structure positions both companies to capitalize on ozekibart's potential across different geographic markets, with Inhibrx leading development in the United States while Transcenta (搜索) focuses on the Greater China opportunity.